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Abstract-Aminoglycoside interactions with various phospholipids were measured in three model 
systems and compared with the ototoxicities of the drugs: (a) competition for [ “‘Clneomycin binding; 
(b) competition for “5CaZ+ binding; and (c) effect on surface pressure of monomolecular lipid films. The 
efficacies of the antibiotics in displacing neomycin from phosphatidylserine, phosphatidylinositol or 
phosphatidylinositol bisphosphate were netilmicin > neomycin 2 gentamicin; the efficacies in displacing 
calcium from phosphatidylinositol, phosphatidylinositol phosphate or phosphatidylinositol bisphosphate 
were netilmicin > gentamicin > neomycin % kanamycin > spectinomycin. Neither measure correlated 
well with the ototoxicities of the drugs which were quantitated at equimolar drug concentrations in 
cochlear perfusions: neomycin > gentamicin 2 tobramycin > netilmicin 2 amikacin. When mono- 
molecular films of phosphatidylcholine with phosphatidylserine, cardiolipin, phosphatidylinositol, or 
phosphatidylinositol phosphate or bisphosphate were challenged with neomycin, the phosphatidylinositol 
bisphosphate film showed a unique dose-dependent increase in surface pressure while the others showed 
a decrease or no significant effect. The abilities of aminoglycosides to increase the surface pressure of 
a film of phosphatidycholine : phosphatidylinositol bisphosphate (1: 1 molar ratio) in the presence of 
3 mM CaCl, correlated well with their toxicities. Non-ototoxic cations increased the film pressure or left 
it unaffected. The results confirm the unique interactions between aminoglycosides and phos- 
phatidylinositol bisphosphate as a possible basis of a mechanism of toxicity and development of a drug- 
screening system. 
The ototoxicity of aminoglycosides is of special clini- 
cal significance because of the potential for per- 
manent loss of inner ear function. Symptomatic audi- 
tory and vestibular ototoxicity occurs in about 2% 
[l] and asymptomatic ototoxicity occurs in about 
10% [2,3] of treated patients. Almost 40 years after 
the discovery of this class of powerful antibacterial 
agents, their ototoxicity is still not understood at the 
molecular level and neither is their nephrotoxicity. 
A wide variety of aminoglycoside-induced alter- 
ations of cell metabolism has been reported, leading 
to hypotheses or model systems that attempt to 
explain the mechanisms of oto- or nephrotoxicity. 
These model systems generally rely on a primary 
interaction between an aminoglycoside and a 
“target” compound such as muccopolysaccharides 
[4], phospholipids [5,6] or even anionic dyes [7]. 
A number of independent studies on cochlear and 
renal lipid metabolism and on physicochemical 
models now strongly implicate anionic phospholipids 
as receptors for aminoglycosides [8,9]. Furthermore, 
our previous work on phospholipid-aminoglycoside 
interactions in vivo [lo] and in vitro [ll] suggests 
that the polyphosphoinositides are specific binding 
sites, and a monomolecular film of these lipids was 
introduced as a model for ototoxicity testing [5, 121. 
A number of points, however, remained unresolved: 
(1) What is the relative importance of phos- 
phatidylinositol phosphate and bisphosphate with 
t Author to whom all correspondence should be 
addressed. 
respect to the interaction of “polyphosphoinositides” 
with aminoglycosides? 
(2) Will measurements of drug binding or calcium 
displacement with isolated lipids show toxicity- 
related interactions in vitro or are more complex 
experimental conditions required, e.g. those which 
measure resultant physicochemical membrane 
changes? 
(3) Can a model system be devised to differentiate 
toxicities accurately and independently of the mag- 
nitude of the positive charge of the drugs? 
We have attempted to refine our model in order 
to clarify the above issues and to test critically the 
postulate of phosphatidylinositol bisphosphate as a 
receptor site for aminoglycosides. 
MATERIALS AND METHODS 
Phosphatidylserine, phosphatidylinositol, and car- 
diolipin were purchased from the Sigma Chemical 
Co., St. Louis, MO. Phosphatidylcholine was 
purified from crude egg lecithin on an alumina 
column. Phosphatidylinositol phosphate and phos- 
phatidylinositol bisphosphate were prepared from 
Sigma brain extract by chromatography on immobi- 
lized neomycin [13]. Neomycin sulfate, reagent 
grade, was purchased from the Sigma Chemical Co.; 
gentamicin and netilmicin sulfate were gifts from the 
Schering Corp., Bloomfield, NJ; tobramycin was 
from the Eli Lilly Co., Indianapolis, IN, and ami- 
kacin from Bristol Laboratories, New York, NY; 
neamine and methylneobiosamine were from the 
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Upjohn Co., Kalamazoo, MI. [G-14C]Neomycin was 
a gift of Dr. G. Flynn, College of Pharmacy, Uni- 
versity of Michigan. 
The water used was thrice distilled, the second and 
third time in an all-glass apparatus. The buffer in all 
the experiments was 0.05 M HEPES (N-Zhydroxy- 
ethyl-piperazine-~-2-sulfonic acid), pH 7.0, ionic 
strength 0.2. The sodium chloride used to adjust the 
ionic strength was heated previously for 12 hr at 700”. 
Phosphatidylinositol phosphate and phosphatidyl- 
inositol bisphosphate were stored dried; other lipids 
were kept in chloroform:methanol (95: 5, v/v) in 
the dark under nitrogen at -20”. The lipids were 
examined prior to use by TLC and estimated to be 
at least 95% pure. 
Binding studies were carried out in a biphasic 
(chloroform : water) system. The aqueous phase was 
200 1.11 of 187mMNaCl in 50mM sodium HEPES, 
pH 7.4; the organic phase was 200 ~1 of 0.1 mM lipid 
in chloroform : methanol (9 : 1). For neomycin dis- 
placement, [ r4C]neomycin (1.3 mC~mmole) and the 
competing aminoglycoside were added at con- 
centrations of 0.1 FM to 1 mM. For calcium dis- 
placement, j5CaZ’ was included in the aqueous phase 
at 0.1, 0.125, 0.17, 0.25, 0.5 and 1mM and the 
competing aminoglycosides at 0.1 ,uM to 1 mM. 
Radioactive neomycin or calcium in the chloroform 
phase was considered as lipid-bound, and blanks 
without lipid served as controls. Analyses were by 
Lineweaver-Burk and Scatchard plots. 
Cochlear perfusions. Perilymphatic perfusions 
were carried out in male albino guinea pigs (200- 
250 g) as previously described [14]. In brief, glass 
capillaries were implanted into the basal turns of the 
Scala tympani and the scale vestibuli of the cochlea 
after a conventional ventral surgical approach. Arti- 
ficial perilymph with or without 10mM amino- 
glycoside was perfused for 60 min at a rate of approxi- 
mately 30#,/min. The cochlear microphonic po- 
tential was monitored continuously via a recording 
electrode in the Scala tympani in response to broad- 
band noise (50 Hz to 10 kHz) delivered by a cali- 
brated earphone attached to a speculum placed 
directly before the tympanic membrane. An intensity 
of 70 dB normally yielded a response of 250-330 pV. 
Animals with a microphonic potential of less than 
200 PV were excluded from the studies. 
Monofayer studies. The subphase consisted of 
0.05 M HEPES (pH = 7, p = 0.2), and its surface 
was swept clean by vacuum suction. The film-forming 
lipid was spread in hexane : ethanol (95 : 5, v/v) to the 
required initial surface pressure. A stationary 5 ml 
syringe, whose needle remained below the film 
throughout the experiment, delivered the drug into 
the subphase which was stirred by a Teflon-coated 
magnetic bar at low speed without disturbing the 
lipid film. The surface pressure was measured by the 
Wilhelmy plate method, with a roughened platinum 
plate suspended from a torsion balance which was 
sensitive to surface pressure changes of 0.1 dyn/cm. 
The film was allowed to stabilize for 30min before 
various concentrations of cationic compounds were 
injected into the subphase. Ten minutes of stirring 
preceded each surface pressure reading. Each run 
was in duplicate, and reproducibility was usually 
within 0.1 to 0.2 dyn/cm. 
RESULTS 
binding studies. The affinities of various amino- 
glycosides to phospholipids were determined by 
their abilities to displace [ i4C]neomycin. Neomycin 
binding to phosphatidylserine or phosphatidyl- 
inositol showed conventional Lineweaver-Burk 
and Scatchard plots: phosphatidylinositol, K, = 
229 * 68 PM; phosphatidylserine, two sites K,, = 
59 + 1 PM, K,,,,, = 265 2 120 /lM. Neomycin binding 
to phosphatidylinositol bisphosphate was complex, 
indicating positive cooperativity similar to obser- 
vations made for calcium binding (below). Relative 
binding affinities were therefore assessed by neo- 
mycin displacement at fixed drug concentrations 
(Table I). As expected, at equimolar concentration 
neomycin (USP grade) displaced about 50% of the 
radiolabeled compound. With phosphatidylserine 
and phosphatidylinositol, netilmicin was significantly 
more effective than gentamicin or neomycin. With 
phosphatidylinositol bisphosphate the three drugs 
were equally effective. 
Calcium displacement. Calcium binding to phos- 
phatidylinositol and phosphatidylinositol phosphate 
showed a single binding site, each with K, = 
0.87 ? 0.42 mM (N = 17) and K, = 0.40 2 0.30 mM 
(N = 3) respectively. Inhibitor constants (Table 2) 
ranked netilmicin, gentamicin, and neomycin highest 
while kanamycin and spectinomycin were con- 
siderably less inhibitory. Calcium binding to phos- 
phatidy!inositol bisphosphate showed positive coop- 
Table 1. Displacement of [ Vjneomycin from phospholipids* 
Competing 
drug added 
[ ‘lC]neomycin (nmoles bound/@mole lipid) 
PhS Phi PhIP> 
None 94 t 13 (100%) 50 + 6 (100%) 5.2 zk 2.4 (100%) 
Neomycin 56 t 9 (59%) 26 k 3 (52%) 2.4 t 1.3 (46%) 
Gentamicin 60 c 8 (64%) 22 2 3 (44%) 2.5 rt: 0.5 (48%) 
Netilmicin 43 t W (46%) 15 -t 3-1: (30%) 2.4 I 1.1 (46%) 
* Binding of [ ‘“Cjneomycin (0.5 mM) was determined as described in Mat- 
erials and Methods. All drugs were added at 0.5 mM. Numbers are means f S .D. 
of five determinations each. Abbreviations: PhSI phosphatidylserin~: Phi, pho- 
sphatidylinositoi; and PhIPz, phosphatidylinositol bisphosphate. 
t Differs from gentamicin (P < 0.01) and neomycin (P = 0.04). 
$ Differs from gentamicin and neomycin (P < 0.01). 
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Table 2. Effects of aminoglycosides on calcium binding to I I I I I I I 
phospholipids* 
K, (PM) &so (PM) 
Competing drug Phi PhIP PhIPz 
Netilmicin 623 95 11 10 
Gentamicin 30 + 20 722 31 
Neomycin 40 ? 25 53 + 37 44 
Kanamycin 363 ? 208 328 + 276 3000 
Spectinomycin 1772 2 11 411 ” 24 >3000 





erials and Methods. K, values are the means 2 S.D. of 
three to five determinations each. KDso (at 1 mM Ca*+) is 
extrapolated by linear regression analysis from two experi- 
ments at three different drug concentrations each. Abbrevi- 
ations: Phi, phosphatidylinositol; PhIP, phosphatidyl- 
inositol phosphate; and PhIP,, phosphatidylinositol 
bisphosphate. 
w 
NEOMYCIN I- log M 1 
erativity and multiple binding sites (details to be 
published elsewhere). Displacement of calcium was 
determined as KDsO, i.e. the concentration of a drug 
necessary to displace 50% of calcium at 1 mM Ca** . 
The rank order of inhibition was essentially the same 
as with the other lipids. 
Monomolecular films. Interaction between neo- 
mycin and various purified acidic phospholipids in 
monomolecular films were investigated previously 
by Lodhi et al. [12]. We now tested mixtures of 
various acidic phospholipids with phosphatidyl- 
choline to examine how the acidic phospholipids 
behave upon addition of calcium and neomycin in 
the presence of a neutral phospholipid. 
Fig. 1. Changes in surface pressure in response to 
neomycin. Monolayers of phosphatidylcholine : acidic 
phospholipid (1: 1) were spread over 0.05 M sodium 
HEPES, pH 7.0, in the presence of 3 mM CaClz at n, = 
12.5 dyn/cm. Neomycin was added, and n was determined 
as described in Materials and Methods. Lipids mixed 
with phosphatidylcholine: (O--O), none or phosphat- 
idylserine; (B-m) cardiolipin; (A-A) phosphat- 
idylinositol; (M) phosphatidylinositol phosphate; 
and (U), phosphatidylinositol bisphosphate. 
The choice of experimental parameters (1: 1 mole 
ratio of phosphatidylcholine : acidic phospholipid, 
ni = 12.5, 3 mM Ca*+) was based on a number of 
pilot experiments. While most of the pure phospho- 
lipids produced stable monolayers, phosphatidyl- 
inositol bisphosphate monolayers were unstable 
(desorbed into the subphase) and required at least 
an equimolar amount of egg lecithin to maintain 
physical stability. Phosphatidylcholine was chosen as 
the neutral phospholipid since its film does not 
change pressure upon addition of neomycin (Fig. 1). 
Mixed films of phosphatidylcholine and phosphat- 
idylinositol bisphosphate at a higher molar ratio of 
2: 1 gave essentially similar results, but lacked sen- 
sitivity, i.e. showed a reduced magnitude of inter- 
action with aminoglycosides. An initial surface press- 
ure (ni) of 12.5 dyn/cm was chosen since the effect 
of aminoglycosides was independent of JCi in the 
range of 9-21 dyn/cm. The stabilities of the mixed 
lipid films were confirmed by following the changes 
in surface pressure of the films over the period of 
time required to conduct the experiments (3 hr). 
All mixed lipid films maintained a constant surface 
pressure after equilibration. 
centrations is not fully understood. It is possible that 
the segregation of the phosphatidylinositol bis- 
phosphate and phosphatidylcholine molecules in the 
film varies with the concentration of Ca*+ . At 3 mM 
Ca*+, the spacing between the molecules may be 
optimal for the interaction of neomycin with pho- 
sphatidylinositol bisphosphate. 
The change in surface pressure of various anionic 
phospholipid-phosphatidylcholine (1: 1) films was 
measured as a function of neomycin concentration 
(Fig. 1). Films of phosphatidylinositol-phosphatidyl- 
choline, and cardiolipin-phosphatidylcholine were 
condensed, whereas films of phosphatidylserine- 
phosphatidylcholine were unaffected by addition 
of neomycin. The surface pressure of phosphat- 
idylinositol phosphate-phosphatidylcholine films 
increased slightly starting at 10m5M neomycin, 
whereas that of phosphatidylinositol bisphosphate- 
Table 3. Effect of calcium on neomycin-induced changes 
of surface pressure* 
Changes of surface pressure (An) 
Neomycin Calcium 
(M) 1mM 2mM 3mM 4mM 5mM 
While the effect of neomycin on the lipids was 
not affected drastically by the above parameters, its 
magnitude was dependent on Ca*+ concentration 
(Table 3). The greatest change in surface pressure 
was induced at 3 mM Ca2+. The slight decrease in 
the change of surface pressure at higher Ca*+ con- 
1.6 x 1O-6 0.35 0.75 1.2 0.8 0.85 
4.0 x 10-d 0.75 1.8 2.4 1.8 1.8 
* Films of phosphatidylinositol bisphosphate-phosphat- 
idylcholine (1: 1) at n, = 12.5 dyn/cm were formed in the 
presence of various amounts of calcium and challenged 
with neomycin as described in Materials and Methods. 
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Fig. 2. Change in surface pressure induced by various 
aminoglycosides. Monolayers of phosphatidylcholine : 
phosphatidylinositol bisphosphate were spread over 0.05 M 
sodium HEPES, pH 7.0, in the presence of 3 mM CaClz at 
ni = 12.5 dyn/cm. Drugs were added, and surface pressure 
was determined as described in Materials and Methods. 
Key: (a) neomycin; (b) gentamicin; (c) tobramycin; (d) 
netilmicin; (e) amikacin; (f) spectinomycin; (g) neamine 
and (h) methylneobiosamine. Data points are not shown 
for the sake of clarity. Each curve represents at least ten 
data points. 
phosphatidylcholine films increased greatly starting 
at very low neomycin concentrations (lo-* M). 
Next, the change in surface pressure of pho- 
sphatidylinositol bisphosphate-phosphatidylcholine 
(1: 1) films was determined as a function of amino- 
glycoside concentration (Fig. 2). The two non-oto- 
toxic fragments of neomycin, neamine and methyl- 
neobiosamine_, condensed the film. All amino- 
glycosidic antibiotics tested, with the exception of 
spectinomycin, expanded it to some degree. 
Spectinomycin, a clinically used aminocyclitol drug 
for treating gonorrhea, is not considered to be oto- 
toxic [15]. Neomycin, highly ototoxic, induced the 
greatest increase in surface pressure, gentamicin and 
tobramycin an intermediate increase, while netil- 
micin and amikacin were the least effective. The 
magnitude of the individual interactions varied with 
the calcium concentration as discussed earlier for 
neomycin; the rank order of the aminoglycosides, 
however, remain unchanged. 
Cochlearperfusions. The toxicities of these amino- 
glycosides were tested in cochlear perfusions. Irre- 
versible loss of the cochlear microphonic potential is 
the measure of ototoxicity quantitated either by the 
initial rate of loss or the loss after 30min of drug 
application (Table 4). Based on this comparison of 
equimolar amounts of drug, neomycin was more 
toxic than gentamicin and tobramycin which, in turn, 
were more toxic than amikacin and netilmicin. Spec- 
tinomycin affected the microphonic potential only 
acutely and reversibly. The recovery induced by Ca*+ 
was in contrast to the irreversibility of gentamicin 
[14] or of even the weakest toxic drug, amikacin. 
Spectinomycin, therefore, did not have the amino- 
glycoside-like toxicity to the cochlear microphonic 
potential. 
Table 4. Effects of aminoglycosides on cochlear micro- 
phonic potentials* 
Drug Loss of microphonic potential 
Experiment A 
Initial rate Loss at 30 min 
(%/min) (“/c) N 
None 0.16 +- 0.12 323 8 
Neomycin 5.37 + 1.44 54 +- 2 3 
Gentamicin 3.40? 1.32 49* 13 15 
Tobramycin 2.50 + 1.20 50 2 13 5 
Netilmicin 1.69 + 0.55 37t 10 5 
Amikacin 1.25 2 0.58 25? 11 6 
Experiment B CM at 30 min CM after wash N 
(% loss) 
Amikacin 32-i- 10 31*9 3 
Spectinomycin 22 t 7 8t 11 3 
* Perfusions were carried out as described in Materials 
and Methods. Experiment A: After an initial control period 
of 30 min, drugs (10 mM, in artificial perilymph) were per- 
fused for 30min. Experiment B: As A. but after drug 
perfusion artificial perilymph with 10 mM Ca*- was per: 
fused for 30min (wash) [14]. Numbers are means ? S.D. 
of N experiments. 
DISCUSSION 
Several criteria have to be met by a viable model 
system of drug action. 
First, the model should be representative of the 
primary membrane action rather than of a secondary 
effect, such as delayed interactions with nucleic acid 
[16] or glycolytic enzymes 1171. 
Second, the model should incorporate the chemi- 
cal uniqueness of the affected organs, i.e. in case of 
aminoglycoside toxicity, the inner ear and kidney. 
Studies based on the interaction of aminoglycosides 
with ubiquitous cellular components such as nucleic 
acids, glycolytic enzymes, or major phospholipids [9] 
do not address the question of why aminoglycosides 
are not toxic to the wide variety of tissues containing 
these compounds. In contrast, tissue distribution of 
polyphosphoinositides is not uniform-high in ner- 
vous tissue and kidney [H-and may account for 
the target specificity of the aminoglycosides. In the 
inner ear, these lipids have been demonstrated in all 
tissues by radioactive labeling [lo, 191 and localized 
to plasma and mitochondrial membranes by immu- 
nohistochemistry [20]. 
Third, the model should encompass the micro- 
environment of the proposed “target” molecule 
rather than treat it as an isolated chemical entity. 
For instance, physiological cations such as Ca’+ 
should be considered since they may crucially modu- 
late drug binding. 
Fourth, the model should predict the relative oto- 
toxicity of a series of aminoglycosides. Although a 
number of model studies do show some degree of 
correlation with clinical toxicity, it seems significant 
that netilmicin generally ranks as too toxic [9, 211, 
and the non-ototoxic drug fragment neamine reacts 
as a “toxic” aminoglycoside [6]. 
A biological receptor site must be considered in 
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its microenvironment. This is particularly true if the 
binding site is part of a membrane structure and fixed 
within definite boundaries. Interactions of a drug 
with the receptor could thus lead to perturbations of 
the orientation, not only of the receptor proper, 
but of larger domains of the membrane, leading to 
changes in membrane fluidity and permeability. For 
example, a given aminoglycoside may interact with 
all negatively charged membrane components; the 
extent of perturbation of membrane structure, how- 
ever, may vary and may not even directly correlate 
with the individual binding constants. Rather, mem- 
brane perturbations and physiological consequences 
will depend on how the primary interaction affects 
the microenvironment of the binding site. 
“Toxicity”, therefore, may be reflected better in 
vitro if the model encompasses some of the com- 
plexity of the natural environment. 
in its interaction with neomycin [23]. Experimental 
comparison with other lipids (Fig. 1) indeed 
confirmed this prediction. While cations in general, 
as well as aminoglycosides, interact with films of 
anionic lipids by decreasing surface pressure, an 
increased pressure is seen in the case of neomycin/ 
phosphatidylinositol bisphosphate. This atypical 
interaction may be based on an electrostatic 3-point 
fit between the negatively charged groups of pho- 
sphatidylinositol bisphosphate and three of the posi- 
tively charged amino groups of neomycin [23]. This 
interaction would displace calcium and orient neo- 
This concept seems clearly supported by the pre- 
sent study. “Simple” interactions such as drug bind- 
ing or calcium displacement do not correlate with 
the toxicity of the drugs. Netilmicin, for example, 
possesses low oto- as well as nephrotoxicity, yet has 
a binding affinity similar to those of the highly toxic 
neomycin and gentamicin. This finding is essentially 
in agreement with a report of gentamicin binding to 
phospholipids and its displacement by other amino- 
glycosides from renal brush border membranes [9], 
which ranked netilmicin between the toxic neomycin 
and tobramycin/gentamicin. As the authors pointed 
out, such a rank order reflects the cationic structure 
of the drugs rather than their toxicities. 
A similar problem of measuring charge rather than 
toxicity was also seen in a study of the influence of 
aminoglycosides on the mobility of liposomes in the 
absence of calcium [6]. The highly charged (+4) 
neamine ranked among the toxic aminoglycosides. 
Neamine must, however, be considered non-ototoxic 
since it is without effect, even when directly intro- 
duced into the inner ear [5]. 
The displacement of calcium represents a some- 
what more complex system as it takes into con- 
sideration the presence of a physiological counterion 
to the acidic lipids. We had shown previously that 
toxic aminoglycosides and non-toxic derivatives all 
compete with calcium binding to synaptosomal mem- 
branes [22]. A recent study by Liillmann and Vollmer 
[21], essentially confirming our earlier work on 
aminoglycoside-lipid interactions, also demonstra- 
ted that the diversely toxic neomycin, gentamicin, 
netilmicin or dibekacin all have approximately the 
same capability of displacing calcium from phos- 
phatidylserine monolayers. The results presented 
here thus confirm and extend the notion that dis- 
placement of calcium alone is not sufficient to explain 
the toxicity of aminoglycosides. 
The model of aminoglycoside-lipid interactions 
that seems to meet all criteria best is based on 
surface pressure changes induced in a mixed mono- 
molecular film of lecithin and phosphatidylinositol 
biphosphate. The latter lipid had been identified as 
a primary site of drug effect in viuo [lo, 191 and as 
a neomycin receptor [ll]. Based on an examination 
of molecular models of various negatively charged 
phospholipids and neomycin, we had postulated that 
phosphatidylinositol bisphosphate should be unique 
mycin in the film such that the resulting complex 
assumes an area-determining position leading to film 
expansion. A penetration of the drug into the film 
may be ruled out as it is energetically highly un- 
favorable because of the strong hydrophilic proper- 
ties of aminoglycosides. 
The rank order of aminoglycosides obtained in 
this system apparently yields an excellent correlation 
with the toxicities of the drugs quantitated by coch- 
lear perfusion. This latter technique introduces the 
drugs (each at the same molar concentration) directly 
into the cochlea and thus measures an intrinsic (or 
potential) toxicity that may be higher than that deter- 
mined in vivo [24]. Drug actions in vivo are influen- 
ced by renal clearance and resulting serum levels as 
well as by the existence of a blood-hemolabyrinthine 
barrier. Further complicating toxicity rankings from 
published in vivo observations is the fact that in most 
studies the aminoglycosides are administered on 
an equal-weight basis or in multiples of their 
clinical dosage. For rational structure-toxicity 
determinations, however, measurement of the intrin- 
sic molecular toxicity is essential. This intrin- 
sic molecular toxicity is obtained from cochlear 
perfusions (neomycin > gentamicin 2 tobramycin > 
netilmicin 2 amikacin) and is in good agreement 
with the toxicities of the drugs as extrapolated from 
clinical observations or in viuo animal studies [25]. 
Spectinomycin as well as neamine and methylneo- 
biosamine [5] are non-ototoxic. 
The refined monolayer system presented here not 
only accurately ranks the toxicities of amino- 
glycosides regardless of their charge but also clearly 
differentiates non-toxic cationic compounds. It is 
primarily the latter aspect that is most improved over 
the previously suggested “polyphosphoinositide” 
monolayer. The study also establishes that, of the 
two polyphosphoinositides, it is phosphatidylinositol 
bisphosphate which is unique in its interaction with 
aminoglycosides. While extrapolations from in vitro 
studies of monolayers to biological membranes must 
be made with caution, the results presented here 
are strongly supportive of the hypothesis that (oto)- 
toxicity of these drugs is mediated through the pres- 
ence of phosphatidylinositol bisphosphate in the 
membranes of affected cells. Efficient drug screening 
and elucidation of structure-toxicity relationships 
may now be based on this drug-receptor interaction. 
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